Most people are aware of type 1 and type 2 diabetes, but did you know there is a type 3 diabetes as well! It is a more obscure term. Although it is not an accepted medical diagnosis, type 3 diabetes has been discussed in the literature as a possible relationship between insulin resistance in the brain and Alzheimer's disease. This link has been described to help explain how metabolic disorders impact brain health, causing cognitive decline and dementia.

What is Type 3 Diabetes?

Type 3 diabetes is more of a misnomer because it should not be confused with type 3c diabetes, which relates to pancreatic dysfunction. The term "type 3 diabetes," on the other hand, has been loosely used by some scientists to analogously propose that Alzheimer's disease is strongly implicated with insulin resistance in the brain.

This concept was conceptualized by Dr. Suzanne de la Monte and Dr. Jack Wands of Brown University in the year 2008. This hypothesis postulated that Alzheimer's disease may be called type 3 diabetes for it bears many similarities with glucose metabolism disorder type 2 diabetes. Their concept arises from the basic principle that insulin is fundamental to blood sugar regulation, but it is also the case with the brain. When brain cells become insulin-resistant, they lose access to glucose, impairing their function.

Research published in the Journal of Diabetes Science and Technology supports this hypothesis by indicating that insulin resistance can be a significant contributor to the occurrence of dementia, also referred to as Alzheimer's. The symptoms of memory loss and diminished reasoning are associated with impaired glucose metabolism in the body, especially in the cerebral tissue.

Symptoms of Type 3 Diabetes

Although type 3 diabetes is not a "medical term," its symptoms correlate well with Alzheimer's diseases that are known to reduce the ability to think in an efficient manner and bring down brain health. These signs are:

- Loss of memory, especially short-term.

- Poor judgment and judgment ability

- Failure in recognizing people or places familiar once.

- Failure in the process of reading, writing or processing numbers

- Anxiety, agitation, or mood changes.

- Disorganized thoughts or confusion

- Lack of impulse control

As the disease advances, patients may be afflicted with severe complications including an inability to swallow or control their bodily functions. In the final stages, most patients die from fatal complications such as aspiration pneumonia.

Causes of Type 3 Diabetes

This may not be well understood with regards to type 3 diabetes, or the exact link between insulin resistance and Alzheimer's disease. Some identified contributing factors include the following:

1. Insulin Resistance

Insulin acts as an important regulatory mechanism of brain functions such as memory and cognition. The reduction in insulin signaling may impair metabolism of brain cells, thus bringing about neurodegeneration.

2. Type 2 Diabetes

These diseases show a strong relationship and those individuals diagnosed with type 2 diabetes have double chances of getting Alzheimer's. In the two, the main causes can be chronic inflammation, oxidative stress, and a defect in glucose metabolism.

3. Environmental and Lifestyle Factors

Insulin resistance associated with obesity, stress, and an unhealthy diet is considered a cause that may increase the chances of Alzheimer's disease.

Researches in Frontiers in Neuroscience and The Lancet Neurology have also highlighted that drugs used for antidiabetic medication may be crucial for the prevention or at least slowing down the course of Alzheimer's.

Treatments for Type 3 Diabetes

In 2022, in a study in Pharmaceuticals, researchers studied biomarker uptake in brain regions implicated in the faulty uptake and metabolism of blood sugar in Alzheimer’s patients.

Emerging Therapies

Research into such treatments as intranasal insulin has also been promising. Intranasal delivery of insulin directly to the brain has been reported to enhance glucose uptake by brain cells, improve memory, and boost cognitive performance. While such clinical trials have been shown to be successful, additional research is needed for safety and efficacy.

Medications

For patients being aggressive or agitated, antipsychotic drugs may be prescribed; however, therapies such as cognitive rehabilitation as well as cognitive stimulation therapy serve to preserve memory and executive function.

Lifestyle Interventions

Diet, exercise, and stress management are critical in preventing and managing insulin resistance. A review in the Journal of Alzheimer's Disease also highlighted the benefits of Kirtan Kriya meditation, which can regulate genes involved in insulin and glucose metabolism, improve sleep, and reduce inflammation.

Can Type 3 Diabetes Be Prevented?

Although type 3 diabetes is not officially recognized, its connection to Alzheimer’s disease underscores the importance of proactive measures for brain health. Some prevention strategies include:

1. Healthy Diet

Consuming a balanced diet rich in antioxidants, whole grains, and healthy fats may support brain health.

2. Regular Exercise

Physical activity improves insulin sensitivity, reduces inflammation, and enhances overall metabolic health.

3. Stress Reduction

Mindfulness practices, including meditation, have been shown to lower stress levels, which can reduce the risk of cognitive decline.

The term type 3 diabetes brings out the complex relationship between metabolic disorders and brain health. Even though it is not a recognized medical condition, the concept emphasizes the crucial role of insulin in brain function and its possible contribution to Alzheimer's disease. Continued research will hopefully provide hope for therapies such as intranasal insulin and lifestyle modifications.

A newly recognised form of diabetes is reshaping how scientists and doctors view the condition, particularly in countries like India. In 2025, global health authorities officially acknowledged Type 5 diabetes as a separate and distinct form of the disease.

This recognition ended decades of confusion around a type of diabetes that did not fit neatly into the existing categories of Type 1 or Type 2 diabetes. The formal classification, backed by the International Diabetes Federation and supported by research published in The Lancet Global Health, is expected to transform diagnosis, treatment, and long-term care for millions of people worldwide.

But what exactly is Type 5 diabetes, and how does it differ from the types of diabetes that are more widely known?

What Is Type 5 Diabetes?

Type 5 diabetes is now recognised as a distinct form of the disease caused primarily by severe, long-term malnutrition, often experienced during childhood. This undernutrition can lead to profound insulin deficiency and an underdeveloped pancreas, resulting in significantly reduced insulin production.

Unlike Type 1 diabetes, which is autoimmune, or Type 2 diabetes, which is linked to insulin resistance, Type 5 diabetes arises from nutritional deficiencies that impair the pancreas’s ability to function properly.

It most commonly affects lean young adults in low-income regions. For years, people with this condition were misdiagnosed as having Type 1 diabetes or an unusual form of Type 2, often leading to inappropriate treatments that failed to address the root cause.

Type 5 Diabetes Symptoms

Symptoms of type 5 diabetes can resemble those seen in other forms of diabetes, such as excessive thirst, frequent urination, persistent tiredness, unexplained weight loss, blurred vision, and slow-healing wounds. However, they are often paired with indications of malnutrition, including a lean physique, delayed growth or puberty in young people, anemia, and recurring infections.

These arise from nutritional deficiencies during early life rather than solely from insulin resistance or autoimmune causes, and they usually present before the age of 30, according to the International Diabetes Federation.

Type 5 Diabetes: Scientists Demand Recognition

Researchers have been studying this condition for decades, particularly in parts of Asia and Africa. Yet, without official recognition, the disease remained poorly understood, and patients were rarely diagnosed correctly. Experts argued that grouping these patients under existing categories obscured the true cause of their illness.

The 2025 classification now formally separates Type 5 diabetes from other types, making it easier to study, identify, and manage. In India, where diabetes prevalence is already high, this recognition is particularly relevant. Tens of millions of people live with diabetes in the country, many of whom remain undiagnosed. Type 5 diabetes highlights a different pattern: it develops not from excess calories, but from too little nutrition during childhood, creating a double burden in regions where obesity and undernutrition coexist.

Implications for Diagnosis and Care

Although there is no new treatment specifically for Type 5 diabetes yet, official recognition marks a major step forward. Doctors can now approach lean patients with a history of malnutrition more carefully, avoiding a “one-size-fits-all” approach. Clearer classification could lead to better guidelines, more personalised care, fewer complications, and improved long-term outcomes.

Experts believe that understanding the role of childhood undernutrition in diabetes could eventually reshape how we prevent, monitor, and manage the condition—something countries like India urgently need as diabetes numbers continue to rise.

An early sign of dementia can sometimes look like a common winter-related issue. When this symptom appears along with other warning signals, it may be wise to speak to a doctor. Dementia is a syndrome marked by a collection of related symptoms that point to a gradual decline in brain function. Over time, this can affect memory, behaviour, thinking, and even movement. In its early phase, however, dementia often shows up through subtle changes that are easy to overlook or mistake for something less serious.

This Common Cold Like Symptom Might Actually Be An Early Sign of Dementia

Dementia UK notes that one possible early indicator of dementia is “low mood, anxiety or depression”. Its specialists explain: “In the early stages of dementia, people often begin to notice symptoms that interfere with day-to-day life.” The difficulty is that low mood or depression can also be linked to seasonal affective disorder (SAD), a form of depression that tends to appear during winter and ease as the days become longer and brighter.

Symptoms of Seasonal Affective Disorder (SAD)

The NHS lists the following possible symptoms of SAD:

• Low mood
• Loss of interest in activities you usually enjoy
• Feelings of guilt, hopelessness or worthlessness
• Feeling restless, tense or easily irritated
• Problems with concentration
• Increased appetite and eating more than usual
• Feeling very tired and sleeping more than usual
• Thoughts of suicide or self-harm

Dementia Early Symptoms

• Problems with memory and concentration
• Difficulties with language and communication, such as struggling to find words or follow conversations
• Difficulties with planning, problem-solving and making decisions
• Getting lost in familiar places because of problems with orientation and reduced ability to recognise usual cues, such as signs or landmarks
• Changes in behaviour and personality, such as becoming more withdrawn or less patient

How Early Symptoms May Differ Between Dementia Types

The organisation explains: “A person experiencing early symptoms of dementia may notice these changes themselves, or they may be picked up first by family members, friends or colleagues. Memory problems are not always obvious in the early stages of some types of dementia, such as frontotemporal dementia, where changes in behaviour and personality may appear first.

“People with young onset dementia, where symptoms begin before the age of 65, are also less likely to have memory loss as an early symptom.”

Emotional Changes Linked To Specific Forms Of Dementia

The charity also points out that emotional changes can be linked to two specific types of dementia. In vascular dementia, a person may experience “changes in mood, behaviour and personality”, while Lewy body dementia can cause “mood changes, including anxiety and depression”.

Dementia: Why These Symptoms Can Be Hard To Identify

That said, it is often difficult to know at first whether dementia is the cause of these warning signs. Dementia UK advises: “Many symptoms associated with dementia can also be caused by other physical or mental health conditions, such as thyroid disorders, menopause, vitamin B12 deficiency, depression, anxiety, work-related stress or relationship difficulties.

“This means that experiencing symptoms linked to dementia does not automatically mean someone has the condition. However, if you or someone close to you is showing signs or symptoms of dementia, it is important to visit a GP to understand what might be causing them.”

When To Seek Medical Advice

If you or someone you know is showing symptoms that resemble dementia, seeking advice from your GP is an important first step.

Gonorrhea poses a far more serious challenge than many realise. Over the years, doctors treating the infection have seen their treatment choices steadily shrink. The bacteria responsible, Neisseria gonorrhoeae, has repeatedly adapted to antibiotics, rendering many once-reliable drugs ineffective. As a result, clinicians have been forced to depend heavily on a single injectable medication, a situation that has raised growing concern.

That dependence is becoming increasingly risky. Data from the US Centers for Disease Control and Prevention show that reported cases of gonorrhea, chlamydia, and syphilis have climbed by nearly 90% since 2004. In 2023 alone, the country recorded more than 2.4 million cases of sexually transmitted infections.

FDA Clears First New Gonorrhea Drug In 30 Years

This month, however, marked a significant shift. The US Food and Drug Administration approved two new oral antibiotics to treat gonorrhea: zoliflodacin and gepotidacin. These approvals represent the first entirely new gonorrhea treatments in more than three decades.

“These approvals mark a significant milestone for treatment options for patients with uncomplicated urogenital gonorrhea,” said Dr Adam Sherwat of the FDA in an official statement.

Why Gonorrhea Has Become Harder to Treat

If left untreated, gonorrhea can lead to serious complications, including pelvic inflammatory disease, infertility, and in rare cases, infections that spread to the joints or bloodstream, as per Cleveland Clinic. Many people experience no symptoms at all, allowing the infection to spread quietly. Despite years of research, there is still no licensed vaccine, leaving antibiotics as the primary line of defence.

What the FDA’s Decision Changes

The newly approved treatments offer a fresh sense of hope. Zoliflodacin, developed by the nonprofit Global Antibiotic Research and Development Partnership in collaboration with Innoviva Specialty Therapeutics, is designed as a single-dose oral medication. Gepotidacin, developed by GSK, is taken in two doses and is also approved for treating certain urinary tract infections.

Both medicines eliminate the need for injections, a shift that could make treatment simpler and more accessible, particularly in settings where access to clinics is limited.

FDA Clears First New Gonorrhea Drug: How the Two New Medicines Work

As per Medscape, clinical trial results for both drugs have been encouraging. Zoliflodacin was tested in a large international study involving more than 900 participants across Europe, Africa, Asia, and the US. The drug successfully cured about 90.9% of patients, a rate comparable to the 96.2% success rate of the current injectable standard. Most reported side effects were mild.

Gepotidacin showed similarly strong results in a separate Phase 3 trial that included around 600 patients from six countries. The cure rate reached 92.6%. Some participants reported digestive issues, but these effects were generally described as mild.

What the Trial Results Show

Importantly, both medications were effective against strains of gonorrhea that no longer respond to older antibiotics. That said, public health experts stress that these drugs are not a permanent solution.

“Bacteria are smart. They can pass resistant mechanisms between each other,” said Dr Manica Balasegaram of the Global Antibiotic Research and Development Partnership, speaking to CNN.

Why Experts Say Caution Is Still Needed

Several uncertainties remain. Neither drug has yet shown strong effectiveness against throat infections, known as pharyngeal gonorrhea, which are more difficult to detect and treat. There is also ongoing debate about how best to use the new medications. Some experts argue they should be reserved as last-line treatments, while others believe earlier use could help slow resistance.

Dr Tereza Kasaeva of the World Health Organization described the approvals as “an important and timely development” amid rising global infection rates and limited treatment options, according to The Guardian.

For now, the new drugs provide much-needed breathing room. Whether that progress holds will depend on careful prescribing and close monitoring of how resistance evolves.